Moderna and Merck's Keytruda vaccine delays recurrence of deadly skin cancer after three years, data says
These results are based on medium-sized trial data the companies released earlier this year that showed the combination’s effectiveness in the same 157 patients over a shorter period of time. After about two years, the vaccine and Keytruda reduced the risk of death or recurrence in melanoma patients by 44% and the risk of the … [Read more…]